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Titanium dioxide (TiO2) nanoparticles are one of the most highly manufactured 
nanomaterials in the world with applications in copious industrial and consumer products. 
The liver is a major accumulation site for many nanoparticles, including TiO2, directly 
through intentional ingestion or indirectly through increased environmental contamination 
and unintentional ingestion via water, food or animals. Growing concerns over the current 
usage of TiO2 coupled with the lack of mechanistic understanding of its potential health 
risk is the motivation for this study. Here we determined the toxic effect of three different 
TiO2 nanoparticles (commercially available rutile, anatase and P25) on primary rat 
hepatocytes. Specifically, we evaluated events related to hepatic functions and 
mitochondrial dynamics: (1) urea and albumin synthesis using colorimetric and ELISA 
assays, respectively; (2) redox signaling mechanisms by measuring ROS production; (3) 
OPA1 and Mfn-1 expression that mediates the mitochondria dynamics by PCR; and (4) 
mitochondrial morphology by MitoTracker Green FM staining. All three TiO2 
nanoparticles induced a significant loss in hepatic functions even at concentrations as low 
as 20 µg/ml with commercially used P25 causing maximum damage. TiO2 nanoparticles 
induced a strong oxidative stress in primary hepatocytes.TiO2 nanoparticles exposure also 
resulted in morphological changes in mitochondria and significant loss in the fusion 
process, thus impairing the mitochondrial dynamics. Although this study demonstrated that 
TiO2 nanoparticles exposure resulted in significant damage in primary hepatocytes, more 
in vitro and in vivo studies are required to determine the complete toxicological mechanism 
on primary hepatocytes and subsequently liver function. 
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Chapter 1 Thesis Introduction and Background  
 
1.1 Nanotechnology and Titanium Dioxide (TiO2) Nanoparticles:  
 
In the last two decades, Nanotechnology has revolutionized industries as diverse as 
engineering, health science and information technology. 1 Novel materials with valuable 
nanoscale properties are being discovered and engineered on large scale to meet with the 
increasing demands in the fields of application. Engineered nanoparticles form a major 
fraction of man-made nanomaterials that is increasing rapidly, escalating in both 
development and commercial implementation in applications such as drug delivery 
systems, antibacterial materials, cosmetics, biosensors, tissue engineering and electronics, 
yielding over thousands of consumer-based products already available in the market.2  
Among engineered nanoparticles, titanium dioxide (TiO2) ranks as one of the most highly 
manufactured and consumed type, from the perspective of both consumer products and 
research applications. 2 3 4  These metal nanoparticles are commercially synthesized in 
rutile and anatase crystal forms. Nanoparticles of TiO2 possess significantly different 
physicochemical properties, compared to the bulk phase, like strong catalytic activity, high 
refractive index, stability and photo sensitivity. 2 These unique properties render the TiO2 
nanoparticles very versatile and find them applications in a wide spectrum of industries 
ranging from water treatment, cosmetics, paint sunscreens, air cleaning, foods, 
sterilization, implants, to pharmaceuticals. 4 5 6 7 8 9 10  
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1.2 Nanotoxicology:  
 
Despite the growing popularity, the largely different repertoire of physicochemical 
properties of nanomaterials gives rise to concerns over their bioactivity profile. 
Nanoparticles are exploited for properties such as small size, increases surface area, higher 
reactivity, aggregation potential, and different optical and electrical properties, as 
compared to their bulk phase counterparts. These differences influence the nature of 
interaction of nanomaterials with biological and ecological systems that were not a concern 
with the bulk material. For example, small particles can enter cells with ease and interact 
with the intracellular macromolecules. 11 They can escape conventional phagocytic 
responses and gain access to circulation and nervous system. 1 Inhalation of nano-
dimensioned material can gain it easy access to respiratory system and the brain. 2 Apart 
from the inherent material properties, the synthesis technique, the route of exposure and 
level of exposure (acute, chronic or sub-chronic) understandably play a crucial role in their 
nature of interaction with biological systems.     
In the event of these concerns, the US Environmental Protection Agency (EPA) and other 
central environmental bodies have expressed their concerns about potential toxicity of 
nanoparticles and are considering measures to limit the use in commercial products and 
increase the government regulations .12 
1.3 Titanium Dioxide Nanoparticle Toxicity:  
 
Metal nanoparticles such as Titanium Dioxide have been used in a variety of common 
consumer products such as food, cosmetics, air/water purifier, medicines, toothpastes and 
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sunscreens. 3 Due to the abundance of commonly found products that contain TiO2, there 
is a high chance of repeated exposure to these particles.  
Various routes of exposure that can lead to the systemic availability of these nanoparticles 
and the most common ones are oral, subcutaneous, dermal, intravenous and lastly, 
respiratory. Respiratory exposure risks are particularly elevated in the form of occupational 
hazard. Previous reports show that over 150 different cosmetic products can lead to long 
term dermal exposure of titanium dioxide nanoparticles (Fig. 1). The whitening properties 
of TiO2 nanoparticles renders them useful as a food colorant. A recent study demonstrates 
the various common food products that have these nanoparticles in them (Fig. 2), along 
with the likely daily exposure to humans of various age groups (Fig. 3). 3 Repeated use of 
TiO2 containing nanoparticles can lead to chronic level exposure and accumulation in 
various organs.  
 
Figure 1. Quantification of Titanium Dioxide Nanoparticles in Various Cosmetic Products 
Published in: Alex Weir; Paul Westerhoff; Lars Fabricius; Kiril Hristovski; Natalie von Goetz; Environ. Sci. 
Technol.  2012, 46, 2242-2250. Copyright © 2012 American Chemical Society 
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Figure 2. Quantification of Titanium Dioxide Nanoparticles in Various Food Product Groups 
 
 
Figure 3Consumption of TiO2 according to age group 
 
 
 
Published in: Alex Weir; Paul Westerhoff; Lars Fabricius; Kiril Hristovski; Natalie von Goetz; 
Environ. Sci. Technol.  2012, 46, 2242-2250. Copyright © 2012 American Chemical Society 
Published in: Alex Weir; Paul Westerhoff; Lars Fabricius; Kiril Hristovski; Natalie von Goetz; 
Environ. Sci. Technol.  2012, 46, 2242-2250. Copyright © 2012 American Chemical Society 
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Several research groups have studied the toxicological behavior of TiO2 nanoparticles 
using in vivo and in vitro models. The effects elicited by these particles on the respiratory 
system are most elaborately studied. 13 14 15   Multiple studies on animal models have shown 
that exposure to TiO2 nanoparticles has led to detrimental responses like Reactive Oxygen 
Species (ROS) generation, increased immune response, triggering of inflammation and 
accumulation in the system.  Multiple cases of in vitro studies on various different sources 
of cells have also shown phenomena of apoptosis and genotoxicity, upon exposure of these 
nanoparticles. 
1.4 The liver and Nanoparticle toxicity:  
 
The liver is a multicellular organ that performs numerous vital metabolic, synthetic and 
clearance-related functions in mammals.  Hepatocytes account for approximately 80% of 
the liver mass and perform essential metabolic functions in the normal and diseased liver.  
Studies demonstrate that the liver is a major accumulation site for many nanoparticles, 
directly through intentional ingestion or indirectly through nanoparticle dissolution from 
food containers or secondary ingestion of inhaled particles.11, 16-18 Additionally, increased 
environmental contamination and unintentional ingestion via water, food or animals may 
also result in further contact and subsequent accumulation of nanoparticles in the liver.11, 
19, 20 Being the primary site for exposure to numerous nanoparticles renders the liver a high 
risk-site for damage from these foreign materials. 
Studies on the bio-distribution of TiO2 nanoparticles have depicted the liver as one of the 
principal sites in the body for accumulation.16, 21 The concern about adverse health effects 
of low-level exposure to TiO2 is imperative to address, particularly study regarding TiO2 
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exposure leading to liver degeneration by impairing mitochondrial bioenergetics. As a 
means to address these concerns and to establish the toxicological profile of TiO2 
nanoparticles, various groups have studied the effects elicited by these particles on different 
biological systems, both in vitro and in vivo.13, 22 Few studies provide evidence of impaired 
mitochondrial bioenergetics and apoptotic cell degeneration after low-level exposure to 
TiO2. 
23, 24
 There is a plethora of published literature on acute TiO2 toxicity, however, the 
effect of TiO2 exposure on the hepatocyte mitochondria and its implications on liver remain 
to be investigated. 
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Thesis Overview:  
 
This thesis focuses on identifying and characterizing titanium dioxide nanoparticles that 
are commonly used in commercial applications and investigating the perturbations in liver 
behavior and mitochondrial characteristics caused by exposure to these TiO2 nanoparticles, 
in order to broaden our understanding on the molecular mechanisms of liver dysfunction 
induced by these highly utilized nanoparticles. Chapter 2 describes the preparation of 
nanoparticles suspensions and characterization. Chapter 3 focuses on developing primary 
rat hepatocytes as our model liver system to investigate the concentration and type 
dependent toxic effects of TiO2 nanoparticles on hepatic functions. Chapter 4 describes our 
findings about the mechanistic aspects that could trigger the changes observed in primary 
hepatocytes, upon treatment with TiO2 nanoparticles. Chapter 5 contains the overall 
summary of the results obtained and potential future directions that will aid in the deeper 
understanding of the effects of TiO2 nanoparticles on the liver cells.  
   
 
 
 
 
 
 
8 
 
 
 
Chapter 2 Characterization of Titanium Dioxide Nanoparticles  
 
2.1 Introduction 
 
2.1.1 Importance of Nanoparticle Characterization:  
 
Nanoparticle characterization plays an important role in interpreting and comparing the 
toxicological effects elicited by the different types of TiO2 on the specific biological 
system. TiO2 nanoparticles are typically available in the anatase or rutile crystal forms. 
Parameters such as particle size, crystal phase and aggregation potential influence their 
bio-activity. 25 Different crystal forms of the nanoparticle have previously been shown to 
elicit different toxicological responses.  Anatase crystal has been shown to possess higher 
reactivity of the two crystal forms.  26 The mechanism of toxicity elicited by the particles 
are also different. Previous studies show that anatase crystals can lead to cell necrosis and 
membrane leakage. Some studies also show that generation of Reactive Oxygen Species 
(ROS) occurs, whereas a few groups observe otherwise. 27 28 On the contrary, rutile 
particles were shown to initiate apoptosis through ROS formation. 28 Variations with 
respect to initial particle size have also been observed by several groups. 26 These different 
results demonstrate the importance of characterizing the physicochemical parameters of 
the nanoparticle type in question, in order to fully understand and profile the toxicological 
behavior elicited by it. Fig. 4 is a cartoon representation of rutile and anatase crystal forms 
of TiO2 nanoparticles. 
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Figure 4. Schematic Representation of Rutile and Anatase Crystal shapes of Titanium Dioxide 
Nanoparticles 
 
2.1.2 Nanoparticle Selection for the Study:  
 
We chose three commercially available forms of TiO2 nanoparticles (anatase, rutile and 
Degussa P25) for our study to determine their toxicological effects on primary rat 
hepatocytes. These particles were selected due to their higher potential of human exposure 
through abundance in consumer products and availability in water sources. Our study 
focused on investigating the crystal phase dependent effects of titanium dioxide 
nanoparticles on the cells. To keep crystal phase as the only variable, we chose pure rutile 
and pure anatase samples of same particle size of 50 nm. Degussa P25, a commercially 
available TiO2 nanoparticle type is a mixture of both anatase and rutile. These three TiO2 
nanoparticles are referred to as anatase, rutile and P25 in the thesis hereon.  
 
 
Rutile Anatase 
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2.2 Materials and Methods 
 
2.2.1 Preparation of TiO2 nanoparticle suspensions 
 
Degussa P25 was obtained from Sigma Aldrich, St. Louis, MO. Pure rutile 50nm, and pure 
anatase 50nm were purchased from MK Nano, Mississauga, Ontario, Canada. The 
nanoparticles were UV sterilized and stock suspensions were made in sterile Phosphate 
Buffer Saline (PBS) at pH 7.4, mixed for 2 minutes, sonicated [FS30D Fisher Scientific] 
for 30 min and stored in dark at 4 ºC until use.  
2.2.2 Dynamic Light Scattering  
 
TiO2 Nanoparticle size and zeta potential were measured using a NanoBrook ZetaPALS 
zeta potential and dynamic light scattering instrument [Brookhaven instrument, Holtsville, 
NY]. Desired concentrations of nanoparticle suspensions were prepared by dilution with 
Hepatocyte culture medium (described in Chapter 3). Mean hydrodynamic diameter was 
measured at a scattering angle of 90°, and the Zeta potential was calculated from Mobility 
measurements by using the Smoluchowski model. All measurements were performed at 25 
ºC at a pH of 7.4. 
2.2.3 Transmission Electron Microscopy 
  
  
Stable suspensions of the different nanoparticles was prepared in DI water using sonication. 
The samples were prepared for imaging by sequential drying steps on copper grids [Ted 
Pella, Inc., CA] that were coated with carbon. Hitachi H7500 TEM was used for analyzing 
the samples.  
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2.3 Results 
 
2.3.1 Aggregation and Surface Charge of the Nanoparticles 
 
TiO2 nanoparticles aggregates in aqueous hepatocyte media were characterized using DLS.  
The purity of the starting nanoparticles was over 95%. To measure the hydrodynamic 
diameter of the aggregates and their resultant zeta potential, working concentration of 
nanoparticles suspension were prepared in hepatocyte media in the identical manner in 
which they are prepared for the cell culture studies. As shown in Table. 1, P25, anatase, 
and rutile nanoparticles aggregated to average diameter of approximately 800nm, 700nm, 
and 380nm, respectively. The aggregate hydrodynamic diameter did not vary significantly 
with the varying concentration of the nanoparticles, in all three sample types (Fig. 5). Zeta 
potential were also measured for the three TiO2 nanoparticles (Table. 1). The zeta potential 
values did not change significantly in the three forms of the nanoparticles and in all three 
concentrations.  
 
2.3.2 Particle Size and Shape of the Nanoparticles 
 
TEM was used to define the individual crystal shapes and sizes of the different TiO2 
nanoparticles (Fig. 6). Anatase TiO2 nanoparticles displayed the characteristic spherical 
crystal structure, with each particle size around 50nm and rutile nanoparticles displayed a 
typical rod-like crystal structure. P25, which is a 3:1 mixture of anatase and rutile, had 
crystals characteristic of both anatase and rutile. These results were in agreement with the 
manufacturer’s specifications and previous reports on the characterization of the shape of 
the nanoparticles.21, 25, 26 
12 
 
 
 
 
 
Table 1.  Characterization of TiO2 nanoparticles aggregates forming in hepatocyte culture 
medium using Dynamic Light Scattering (DLS) at 37 ºC and pH of 7.4. 
Figure 5. Comparison of Hydrodynamic Diameters of Nanoparticles in Different Concentrations 
13 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Transmission Electron Microscopy images to characterize the crystal shape of the TiO2 
NPs as seen in DI water; (a) P25, (b) Anatase, 50 nm particle size and (c) Rutile , 50 nm particle 
size, scale = 50 nm 
   
 
 
A B 
C 
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2.4 Discussion 
 
Nanoparticle characterization plays a vital role in interpreting and comparing the 
toxicological effects elicited by the different types of TiO2 on the specific biological 
system. We chose three commercially available forms of TiO2 nanoparticles (anatase, rutile 
and P25) for our study to determine their toxicological effects on primary rat hepatocytes. 
Our TEM results indicate that the crystal structure of anatase was spherical, rutile was rod 
shaped and P25 had a mixture of both the crystal structures. (Fig. 6) TiO2 nanoparticles 
have the tendency to form aggregates in aqueous media that have high ionic strength. To 
compare the level of aggregation of the TiO2 nanoparticles in physiologically relevant 
conditions including the presence of proteins and divalent ions, we studied the aggregation 
nature of the TiO2 nanoparticles in serum containing hepatocyte culture media. As seen in 
Table. 1, the aggregation did not vary significantly with the concentration of the 
nanoparticle suspension, within the same type. For the variation of the aggregate sizes 
between the different nanoparticles, the type of crystal structure of the particles (anatase vs 
rutile) and the relative composition of the three forms of nanoparticles might attribute to 
the observed variations in their aggregation sizes.  
In agreement with the aggregation in the physiologically relevant media, the zeta potential 
for all three TiO2 crystalline forms, regardless of concentration, was measured to be within 
the realm of colloidal instability. Our extensive characterization provides us with valuable 
information about the physicochemical properties of the different type of particles the cells 
are interacting with when they are exposed to TiO2. 
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2.4 Conclusion 
 
We were able to characterize the individual particle shape and size using TEM and 
observed a typical crystal shape of rod-like in rutile and spherical in anatase, consistent 
with the previous reports on similar characterization. With the DLS study, we were able to 
characterize the hydrodynamic diameter and zeta potential of the different titanium dioxide 
nanoparticles in hepatocyte medium. These characterizations will prove useful in 
correlating our observations with the inherent physicochemical behavior of the particles.  
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Chapter 3 Effect of Titanium Dioxide Nanoparticles on Primary 
Hepatocyte Viability and Functions  
 
3.1 Introduction 
 
3.1.1 TiO2 Nanoparticles mediated Toxicity to The Liver  
 
Exposure routes such as respiratory, oral, intravenous and dermal have scope for systemic 
access to foreign particles. Previous reports on the bio-distribution of TiO2 nanoparticles 
suggest high likelihood for the particles to reach the liver and accumulate. 22 29 Study by 
Fabian et al demonstrates that traces of nanoparticles were found in the liver 28 days after 
intravenous exposure to anatase and rutile TiO2 nanoparticles. 
30 Cui et al showed that 
prolonged intra-gastric instillation of TiO2 Nanoparticles causes NF kB mediated 
inflammation, followed by apoptosis in the liver of mice models.  31  
Some recent in vitro studies have also investigated the toxicity of these metal nanoparticles 
on the liver cells. Shi et al showed that human L02 hepatocytes displayed increased 
oxidative stress due to ultrafine TiO2 nanoparticle exposure. 
32 Similar results of oxidative 
stress were observed in BRL 3A rat liver cell line. 33  
Limited number of studies have been carried out in order to explore the mechanistic aspects 
of TiO2 Nanoparticles on hepatocytes. Studies carried out on animal models have the 
limitation of being complex and it is challenging to deduce the observations to a particular 
cell type without accounting for the exogenous factors. Similarly, use of hepatic cell lines 
pose the disadvantage of potential deviation from the actual liver biology owing to the 
transformations cell lines undergo.  
17 
 
 
 
3.1.2 Primary Hepatocytes as in vitro Liver Models  
 
Hepatocytes are the most important cell type of the liver and perform numerous vital 
metabolic, storage and clearance related functions. 34 Primary hepatocytes retain a 
considerable fraction of their complex functions when cultured in suitable conditions in 
vitro. Prolonged culture of hepatocytes leads to loss in the differentiated phenotype and 
this event precedes cell death. To understand the cytotoxicity of nanoparticles, along with 
general end point assays such as quantification of viability and morphology, studying the 
hepatocyte specific phenotypic markers is essential. Hepatocyte specific functions like 
synthesis of albumin and urea are gold standard markers for characterizing the phenotypic 
stability of the cells. 34 We investigated how these functions were affected by the exposure. 
To be able to study cellular events prior to cell death, as a preliminary step before studying 
the cellular markers, we determined the cytotoxicity of the different types of TiO2 
Nanoparticles on primary hepatocytes in order to obtain the lethal concentration value 
(LC50).  
3.2 Materials and Methods 
 
3.2.1 Isolation of Primary Hepatocytes    
 
All animal procedures were carried out in accordance with the guidelines from IACUC of 
University of Nebraska-Lincoln.  Excision of the liver followed by isolation of hepatocytes 
was performed as per the protocol of P.O Seglen and R.Blomhoff  35 with slight 
modifications. Sprague Dawley rats weighing about 160-200g were subjected to 
anesthetic-conditions in a desiccator chamber saturated with 30% isoflurane solution. The 
rats were kept in the chamber till the full effect of anesthesia was confirmed, which is 
18 
 
 
 
limpness of the body and deep respiration. The animal was moved to the surgery table and 
a syringe tube with isoflurane was secured on the snout for assuring prolonged 
unconsciousness. With bandage scissors and forceps, the entire abdominal cavity was 
exposed and vena porta was located. A strand of surgical thread was drawn beneath the 
vena port and an overhand knot was tied. Vein was cannulated with Insyte Autoguard 
catheter (18GA, 1.3x300mm, BD Biosciences). The needle was retracted and oxygenated 
Tris Buffer Saline (TBS) was supplied through the catheter at a flow rate of about 
20mL/min and was continued till the liver turned loam colored. Liver was excised out of 
the abdominal cavity by cutting around all the tissues that attach it to the body. Liver was 
placed on a sieved funnel and buffer was allowed to continually flush the blood away. 
Digestion of the liver by collagenase digestion followed next. Collagenase solution of 
strength about 10 mg per 100 grams of rat’s weight was prepared in 60 mL of Calcium 
containing buffer. The TBS flushing was brought to an end and collagenase was pumped 
in through a closed circuit. After about 15 minutes, the liver was transferred to a sterile 
dish containing buffer 1 and Glisson’s capsule and extra tissues, if any, were peeled away. 
The liver was shook in the buffer to detach all the hepatocytes in the liver matrix. And the 
buffer loaded with cells was filtered through 100 µm followed by 30um to get a purer 
population of hepatocytes. The filtrate was centrifuged with buffer 3 and 150xg for 3 
minutes and the process was repeated till the supernatant was clear and the pellet intact. 
The viability of hepatocytes was determined using trypan blue exclusion method, was also 
confirmed using percoll gradient. Viability of 85% and above was considered threshold for 
continuing with culture.  
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3.2.2 Culture and Treatment of Primary Hepatocytes    
 
Before seeding, tissue culture plate surfaces were coated with 100µg/ml rat tail collagen 
type I solution prepared in 0.02 N acetic acid for 1 hour at 37 ºC, washed and stored at 4 
ºC till use. Cells were seeded at a density of 100,000/cm2 on the collagen coated plates. 
Nanoparticle suspensions in the desired concentrations were prepared in the culture media 
and added to the cells. 
Hepatocyte Culture Medium: Culture media was made with high glucose DMEM 
supplemented with 10% FBS, 0.5 U/ml insulin, 20 ng/ml epidermal growth factor (EGF), 
7 ng/ml glucagon, 7.5 mg/ml hydrocortisone, and 1% penicillin-streptomycin. All the 
reagents were obtained from Sigma-Aldrich. 
3.2.3 Cytotoxicity Assay to Determine LC50    
 
The cytotoxicity of nanoparticles was assessed by MTT assay [3-(4,5-dimethyldiazol-2-
yl)2,5 diphenyl Tetrazolium Bromide] [Life Technologies, NY] which quantitatively 
evaluates the mitochondrial conversion of the MTT salt into purple formazan crystals.. 
Nanoparticle solution was removed and 0.5 mg/ml MTT working solution in DMEM was 
incubated on live cells at 37 ºC for 2.5 hours. After incubation the working solution was 
removed and lysis buffer (0.1 N HCl in Isopropanol) added. The lysis buffer was 
transferred to a 96 well plate and absorbance values collected in an AD340 plate reader 
[Beckman Coulter, Brea, CA] at corrected 570/620 nm. Relative absorbance was used as 
the indicator for cell viability. Concentration range of 0 µg/ml to 1000 µg/ml for each 
nanoparticle was used to generate the dose response curve. SigmaPlot software was used 
to calculate LC50 value for each type of nanoparticle.  
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3.2.4 Scanning Electron Microscopy (SEM) 
 
Nanoparticle size and shape were assessed and viewed under a scanning electron 
microscope (SEM) [S-3000N, Hitachi Tokyo, Japan]. Cellular morphology and 
nanoparticle distribution was visualized by SEM. The cells were rinsed with PBS and fixed 
with 4% paraformaldehyde/PBS solution for 15 min. The paraformaldehyde solution was 
removed, samples rinsed with PBS and dehydrated with ethanol solutions (from 20 to 
100%). The sample was incubated for 15 min at room temperature in each solution. The 
100% ethanol solution was removed with hexamethyl disilazane [Sigma Aldrich, USA] 
and the sample was allowed to air-dry. The samples were then coated with gold-palladium 
(Au-Pd) and analyzed under the SEM. 
3.2.5 Live Dead Fluorescent Assay 
 
Cell viability was assessed using a Live/Dead Viability/Cytotoxicity Kit [L-3224 
Invitrogen, Grand Island, NY]. In short, Nanoparticle supernatant was removed and cells 
were washed once with PBS and incubated at 37 ºC for 30 min with assay reagent (4 uM 
EthD-1 and 2 µM Calcein in PBS) at 37 ºC. The cells were removed and washed 3 times 
with PBS and viewed with an Axiovert 40 CFL [Zeiss, Germany] and X-Cite 120Q [Lumin 
Dynamics, Mississauga, Ontario, Canada]. 
3.2.6 Urea Quantification Assay 
 
Urea secretion by hepatocytes in culture medium was assessed every 24 hours using 
Stanbio Urea Nitrogen (BUN) kit [Stanbio, Boerne, TX] using manufacturer’s protocol. 
Briefly, the kit exploits the reaction between urea and diacetyl monoxime which results in 
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a color change with an absorbance of 520 nm read on AD 340 plate spectrophotometer 
[Beckman Coulter, Brea, CA]. 
3.2.7 Albumin Quantification ELISA 
 
Albumin Secretion by hepatocytes into culture medium was measured every 24 hours using 
Rat Albumin ELISA Quantitation Kit from Bethyl Laboratories, Inc [Montgomery, TX] 
according to manufacturer’s instructions. In short, a 96 well plate was coated with a coating 
antibody for 1 hour and blocked with BSA for 30 min. Standard/Sample was added to each 
well and incubated for 1 hour.  HRP detection antibody was incubated for 1 hour followed 
by the addition of TMB Substrate solution which was developed in the dark for 15 min and 
absorbance read on AD340 plate spectrophotometer [Beckman Coulter, Brea, CA] at 450 
nm. 
3.2.8 Cell Morphology Analysis:  
 
Phase contrast images of primary hepatocytes cultured on the different substrates were 
captured using an Inverted Microscope [Axiovert 40 CFL, Zeiss, Germany]. For 
fluorescent viewing of the cell morphology, Calcein AM staining was used [Life 
Technology, NY].  
3.2.9 Statistical Analysis:  
 
The difference between the various experimental groups was analyzed by a one-way 
analysis of variance (ANOVA) using the statistical analysis feature embedded in SigmaPlot 
Software using Tukey test. Q tests were employed to identify outliers in the data subsets. 
For statistical analysis of all data, p<0.05 was used as the threshold for significance. 
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3.3 Results 
 
3.3.1 Cytotoxicity of TiO2 Nanoparticles on Primary Hepatocytes 
  
We evaluated the cytotoxicity of three different TiO2 nanoparticles (P25, anatase and rutile) 
that were selected due to their abundance in commercial products using MTT assay. A 72 
h exposure to the three different TiO2 nanoparticles of varying concentration (0-1000 
µg/ml) to primary hepatocytes established the LC50 value of the different particles. As seen 
in Table. 2, the LC50 values of P25, anatase and rutile TiO2 nanoparticles were 74.13±9.72 
µg/ml, 58.35±4.76 µg/ml, and 106.81±11.24 µg/ml, respectively.  Fig. 7 represents the 
dose response curves plotted using Sigma Plot for the different nanoparticles using non-
linear regression that were used to analyze the LC50 values. After determining the LC50 
values, the concentrations of 20, 50 and 100 µg/ml were chosen for the rest of the studies 
to enable studying the cellular phenomena at a sub-acute dosage range.  
 
 
Table 2: Lethal Concentration (LC50) analysis of the different TiO2 nanoparticles treatment of 
primary rat hepatocytes. 
 
23 
 
 
 
 
 
 
                                                         
Figure 7. Dose response curve to calculate LC50 using four parameter plots for the different 
titanium dioxide nanoparticle treatment on primary hepatocytes  
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To study the concentration dependent effect of TiO2 nanoparticles on primary hepatocyte 
morphology, we observed the cellular characteristics using SEM (Fig. 8). After 72 h of 
exposure to the three chosen concentrations of the nanoparticles, primary hepatocytes did 
not exhibit a marked change in cellular morphology. For all three nanoparticles we 
observed the smooth and spherical morphology of hepatocytes that was comparable to 
untreated cells. 
 
 
 
Figure 8. Scanning Electron Microscopy (SEM) images to visualize the morphology of primary 
hepatocytes when treated with TiO2 nanoparticles after 72 h of exposure. Scale bar: 30 microns. 
Yellow arrows point to primary hepatocytes  
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3.3.3 TiO2 Nanoparticles and Primary Hepatocyte Cell Viability  
 
To quantitatively determine the viability loss in hepatocytes after exposure to TiO2 
nanoparticles, we performed MTT assay. Hepatocytes were treated in the chosen 
concentrations (20, 50 and 100 µg/ml) of P25, anatase, and rutile for 72 h. The exposure 
of hepatocytes to TiO2 nanoparticles showed a concentration and type dependent loss in 
viability (Fig. 9). We normalized the viability of TiO2 nanoparticles treated hepatocytes 
with respect to untreated cells. In P25 treated samples, 91% cells were viable when exposed 
to 20 µg/ml concentration which decreased to 75% at 100 µg/ml concentration. Similarly 
in hepatocytes exposed to anatase nanoparticles, the cell viability significantly decreased 
from 92% in the 20 µg/ml concentration to 66% in 100 µg/ml. However, all three 
concentrations of rutile did not affect the cell viability and had the highest percentage of 
viable cells even at a concentration of 100 µg/ml.  
In addition, to study the effect of nanoparticle treatment after a prolonged duration, we 
performed Live/Dead Fluorescent cell staining as seen in Fig. 10. These results also suggest 
similar phenomenon. Anatase and P25 showed a greater loss in viability as compared to 
rutile and the effect was observed to be concentration dependent.  
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Figure 9. MTT assay to quantify primary hepatocyte viability after treatment with different TiO2 
nanoparticles at 20, 50 and 100 µg/ml after 72 h of exposure normalized to the untreated 
hepatocytes. * p value < 0.001 
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Figure 10. Live/Dead dual fluorescent staining of primary hepatocytes when treated with 
titanium dioxide nanoparticles on Day 7 in culture. Calcein FM stains the live cells green and 
Ethidium Bromide stains the dead cells red. Scale bar: 100 microns. 
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3.3.3 TiO2 Nanoparticles and Primary Hepatocyte Specific Functions  
 
3.3.3.1 Urea Synthesis  
 
We studied the effect of prolonged exposure of hepatocytes to three chosen concentrations 
(20 µg/ml, 50 µg/ml, 100 µg/ml) and types of TiO2 nanoparticles (P25, anatase, rutile) on 
two chief hepatic functions; urea synthesis and albumin synthesis. We quantified the 
amount of urea synthesized by hepatocytes upon treatment with TiO2 nanoparticles, using 
a colorimetric assay (Fig. 11 and Fig. 12). Fig.11 illustrates the urea production of primary 
hepatocytes after 72 h of exposure to different TiO2 nanoparticles. We normalized the value 
of urea and albumin synthesis of the treatment groups with respect to the untreated cells. 
We observed significant concentration and type dependent loss in urea synthesis. The 
exposure of hepatocytes to 20 µg/ml, 50 µg/ml, and 100 µg/ml of P25 resulted in 29%, 
42%, and 57% loss of urea production, respectively. The exposure of hepatocytes to 20, 50 
and 100 µg/ml of anatase resulted in 8%, 20%, and 42% loss of urea production, 
respectively. The exposure of hepatocytes to rutile resulted in negligible loss of urea 
production in all three concentrations compared to untreated cells.  The comprehensive 
quantification of urea synthesis for a week demonstrated similar trend when exposed to the 
different concentrations of the TiO2 nanoparticles Fig. 12.  
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Figure 11. Characterizing the effect of the different TiO2 nanoparticles treatment on primary 
hepatocytes specific functions; Quantification of urea synthesized primary hepatocytes after 72 h 
of exposure normalized to the untreated cells * p value < 0.001, 
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Figure 12. Quantification of urea synthesized primary hepatocytes from day 1 to day 7 in culture 
when treated with the different TiO2 nanoparticles. All the data points are normalized to 
untreated hepatocytes 
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3.3.3.2 Albumin Synthesis  
 
We further quantified the amount of albumin synthesized using sandwich ELISA 
technique. Fig. 13 illustrates the albumin synthesis of primary hepatocytes after 72 h of 
exposure to different TiO2 nanoparticles. We observed significant concentration and type 
dependent loss in albumin synthesis comparable to our data on urea production. The 
exposure of hepatocytes to 20, 50, and 100 µg/ml of P25 resulted in 27%, 41%, and 60% 
loss of albumin production, respectively. The exposure of hepatocytes to 20, 50, and 100 
µg/ml of anatase resulted in 10%, 20%, and 35% loss of albumin production, respectively. 
Akin to the urea production, the exposure of hepatocytes to rutile resulted in decreased 
albumin production in all three concentrations compared to untreated cells. The 
comprehensive quantification of albumin synthesis for a week demonstrated similar trend 
when exposed to the different concentrations of the TiO2 nanoparticles Fig. 14. 
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Figure 13. Characterizing the effect of the different TiO2 nanoparticles treatment on primary 
hepatocytes specific functions; Quantification of albumin synthesized primary hepatocytes after 
72 h of exposure normalized to the untreated cells * p value < 0.001, # p value 0.01 
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Figure 14. Quantification of albumin synthesized primary hepatocytes from day 1 to day 7 in 
culture when treated with the different TiO2 nanoparticles. All the data points are normalized to 
untreated hepatocytes. 
 
3.4 Discussion  
 
Following the nanoparticle characterization, we studied the cytotoxicity of the different 
types of nanoparticles using MTT assay (Table. 2 and Fig. 7). Our observations are in 
agreement with some reports36, 37 and in disagreement with others38 on the cytotoxicity of 
TiO2 nanoparticles. This discrepancy may be due to several reasons including the technique 
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employed in evaluating cellular changes, such as membrane permeability (live/dead 
fluorescent staining and trypan blue assays) versus mitochondrial function (3-(4,5-
dimethylthiazole-2-yl)-2,5-biphenyl tetrazolium bromide or MTT assay) 39. Our result 
indicates that pure anatase and P25 nanoparticles are more cytotoxic compared to rutile 
nanoparticles. This trend is consistent with previous reports comparing the anatase and 
rutile TiO2 nanoparticles.
26  This result also provides us with the range of concentration 
that needs to be addressed to enable complete mechanistic understanding of TiO2 
nanoparticles mediated toxicity in liver cells. These concentrations are in the relevant sub-
acute range, as compared to previous studies that have been carried out focusing on effect 
of TiO2 nanoparticle exposure on liver 
16, 33, 40, 41 Numerous in vitro studies studying the 
toxicity of TiO2 nanoparticle have consistently used high concentrations of the 
nanoparticles, thus limiting these studies to probe mechanistic studies beyond toxicity of 
the nanoparticles26, 42, 43 The purpose of our study is to further investigate how TiO2 
nanoparticles exposure affect primary hepatocytes, with a particular focus on changes in 
cellular phenotype and mechanisms that mediate these changes. As a result we specifically 
chose three concentrations of TiO2 nanoparticles for all the subsequent mechanistic studies 
(20 µg/ml, 50 µg/ml, 100 µg/ml) with 72 h exposures that is reflective of the LC50 data. 
These concentrations fall in the sub-lethal range, thereby permitting us to investigate 
crucial early cellular events, which will yield a better mechanistic understanding of the 
intrinsic factors mediating nanoparticle induced toxicity. 
To determine the effect of the different nanoparticles in the chosen concentration on 
primary hepatocyte morphology, we used SEM imaging. As seen from Fig. 8, the cells did 
not display a marked change in morphology. Hepatocytes did not exhibit significant change 
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in aggregate formation or loss in attachment from the culture substrate. Typically cells that 
are necrotic have distinct surface features in the form of loss of membrane integrity and 
presence of surface lesions. However, such features were missing in hepatocytes exposed 
to all three TiO2 nanoparticles.  
Subsequently, we observed compromise in cell viability through MTT assay which was 
most pronounced in P25 and anatase. The loss in viability was also directly dependent on 
the concentration of treatment. The loss in viability was not significantly pronounced in 
rutile treated samples (Fig. 9).These results indicate that there is a concentration and type 
dependent effect on primary hepatocytes when exposed to TiO2 nanoparticles. Upon 
extending the treatment time, we also observed drastic loss in cell viability when 
hepatocytes were exposed to P25 and anatase for one week while exposure to rutile did not 
show significant change in viability (Fig. 10). This difference in the cell behavior reflects 
on potentially different modes of actions from the different TiO2 nanoparticles on the 
hepatic biology. 
We examined the effect of TiO2 nanoparticle treatment on primary hepatocyte specific 
functions by quantifying urea and albumin synthesis (Fig.11 to Fig. 14). Hepatocyte 
mediated urea production is an indicator of intact nitrogen metabolism and detoxification 
and albumin synthesis is a widely accepted marker of hepatocyte synthetic function. We 
observed significant loss in urea and albumin synthesis function of hepatocytes, which was 
both concentration and type dependent. Exposure to rutile, in line with earlier observations, 
resulted in the least loss in both urea and albumin synthesis.  
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 Animal studies have shown that damage does occur to the liver when exposed to TiO2 
nanoparticles, however, it is challenging to deduce the effect of nanoparticles on a 
particular cell type using an in vivo study. Limited number of in vitro studies has been 
carried out to understand the direct effect of TiO2 nanoparticles on liver using primary 
hepatocytes.33, 40, 44, 45 A major weakness of existing literature about the in vitro effects of 
nanoparticles is that the in vivo dosimetry and biokinetics are largely ignored, i.e., effects, 
if observed, are at high concentrations.46, 47   There is a deficiency in a conclusive result for 
the direct effect of these nanoparticles on hepatocytes functions when exposed to lower 
concentrations of nanoparticles. These results demonstrate that even though the 
hepatocytes have high viability at 72 h, the exposure to P25 and anatase results in 
significant damage to hepatic functions. The most critical observation is the exposure to 
100 µg/ml of commercially used P25 TiO2 nanoparticles for 72 h, though has 77% viable 
cells, results in 60% loss in hepatic functions. We hypothesize that exposure to TiO2 
nanoparticles causes significant stress and damage on important hepatic function even 
when the cells are viable. This suggests that employing cell viability as a sole marker for 
effect of environment exposures including nanoparticles is a weak biomarker to identify 
potential risk factors of these exposures. 
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3.4 Conclusion  
 
We treated primary rat hepatocytes with different types of TiO2 Nanoparticles in a range 
of concentrations to determine the LC50 values that enabled us to select the sub-acute range 
of 20, 50 and 100 µg/ml as the working concentrations for the cellular studies. Hepatocytes 
did not exhibit marked changes in cellular phenotype and only a moderate loss in cellular 
viability at chosen concentrations. We observed a nanoparticle type and concentration 
dependent loss in urea synthesis and albumin synthesis in primary hepatocytes subjected 
to treatment and this effect was most pronounced in P25 treatment groups, closely followed 
by anatase. Rutile treatment resulted in the least loss in hepatocyte functions.  
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Chapter 4 Mechanistic Aspects of Titanium Dioxide Mediated Toxicity  
 
4.1 Introduction 
 
4.1.1 Titanium Dioxide and Oxidative Stress  
 
Numerous studies have demonstrated that metal oxide nanoparticle induced toxicity is 
primarily mediated by increased ROS production.48, 49 A study on HepG2 cells show ROS 
mediated DNA damage in the cells, upon treatment with TiO2 Nanoparticles. 
50 Several 
studies also demonstrate ROS mediated inflammatory response in the animal models. 48 23   
It is well established that, in excess, ROS species can lead to highly detrimental 
macromolecular interaction that can further lead to cellular events such as inflammation, 
mitochondrial damage, membrane disruption and lastly cell death. 51 Mitochondrial 
function and ROS production are mutually dependent where excessive ROS production 
leads to mitochondrial stress and stressed mitochondria, in turn, produce more ROS 
species. 52  Few studies provide evidence of impaired mitochondrial bioenergetics and 
apoptotic cell degeneration after low-level exposure to TiO2. 
23, 24 
4.1.2 The Liver and Mitochondria  
 
Hepatocytes constitute approximately 80% of the liver mass. These cells exhibit high 
metabolic and bio-transforming activity that consequently imposes high energy 
requirements. To meet these energy requirements, hepatocytes contain a high density of 
mitochondria, distributed uniformly throughout the cell body.53, 54 Mitochondria act as the 
vital source of energy in hepatocytes and also play a significant role in extensive oxidative 
metabolism and normal functioning of the liver.55 Inherently, mitochondria have a highly 
dynamic nature; they undergo continual fission and fusion processes which counterbalance 
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each other, to alter the organelle morphology that enables the cell to meet its metabolic 
requirements and cope with internal or external stress.56, 57 Three central players that 
control the process of mitochondrial fission and fusion resulting in the unique structural 
features, have been identified in mammals: (1) Mitofusins 1 and 2 (Mfn-1 and Mfn-2) ; for 
outer-membrane fusion (2) OPA1; for inner membrane fusion and (3) Drp1 for inner and 
outer membrane fission.57 In normal conditions, mitochondrial fusion enhances 
mitochondrial integrity by allowing component sharing across the tubular network. 
However, fusion of highly damaged mitochondria to the network could be detrimental, 
since impaired mitochondria generate reactive oxygen species (ROS) that results in 
significant cellular damage.55, 57   
  
 The concern about adverse health effects of low-level exposure to TiO2 is imperative to 
address, particularly to analyze whether TiO2 exposure leading to liver degeneration by 
impairing mitochondrial bioenergetics. There is a plethora of published literature on acute 
TiO2 toxicity, however, the effect of TiO2 exposure on the hepatocyte mitochondria and its 
implications on the liver remain to be investigated.  
Recent studies demonstrate that several liver diseases, are related to the optimal function 
of mitochondrial dynamics that leads to differential regulation of the fusion and fission 
markers discussed above.58, 59 Mitochondrial oxidative damage has been demonstrated to 
be a major factor in several liver disorders such as nonalcoholic steatohepatitis, Wilson’s 
disease, early graft dysfunction after liver transplantation, alcohol induced liver disease, 
non-alcoholic fatty liver disease, viral hepatitis, cholestasis and chronic hepatitis C.53, 60-64 
The condition of oxidative stress results in the formation of damaging ROS due to continual 
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leaking of electrons from the respiratory chain.52 Functional impairment of mitochondria, 
due to oxidative stress, in hepatocytes is often accompanied by modification of 
mitochondrial proteins, DNA and lipid peroxidation which may lead to mitochondrial 
bioenergetics failure, that eventually leads to compromise in cellular functions and 
subsequent necrotic or apoptotic cell death.52 Fission protein Drp 1 has been linked to cell 
death in previous studies.65 Diminished OPA1 and Mfn (1 and 2) levels have been reported 
in biological systems that are in diseased state.66 Apart from diseases, recent studies have 
demonstrated that exposure to several engineered materials, including nanomaterials, leads 
to structural and functional alterations in mitochondrial membranes.67, 68 
In this study we investigated the perturbations in the liver behavior and mitochondrial 
characteristics caused by exposure to TiO2 nanoparticles in order to broaden our 
understanding on the molecular mechanisms of liver dysfunction induced by these highly 
utilized nanoparticles. We used primary hepatocytes to investigate the concentration and 
type dependent toxic effects of commercially available rutile, anatase and P25 TiO2 
nanoparticles on mitochondrial dynamics and hepatic functions. The results of our study 
indicate that TiO2 nanoparticles induce ROS production, cause mitochondrial damage in 
hepatocytes and compromise normal liver function.  
4.2 Materials and Methods 
 
4.2.1 Reactive Oxygen Species (ROS) Quantification  
 
Reactive Oxygen Species (ROS) production was quantified by a H2DCFDA based 
fluorescence assay. Briefly, the cells were washed to remove traces of serum from the 
culture media and were incubated with 10µM H2DCFDA [Life Technologies, NY] for a 
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duration of 30 min at 37 ºC. After incubation, cells were gently washed and cells were 
trypsinized using TRYPLE select [Life Technologies, NY] and suspended in PBS. The cell 
suspension was transferred to a 96 well plate, which was read at excitation 528 nm and 
emission 405 nm using a SLFA plate reader [Biotek, Winooski, VT]. Hydrogen Peroxide 
treatment was used as a positive control and the untreated hepatocytes were used as the 
experimental control to normalize the fluorescence intensity. 
4.2.2 Gene Expression Studies  
 
4.2.2.1 RNA and cDNA preparation 
 
At each time point total RNA from primary hepatocytes was isolated using RNeasy Micro 
Kit [Qiagen, Valenica, CA] according to the manufacturer’s instructions. Briefly, cells 
were trypsinized, centrifuge pelleted, washed with PBS and lysed in RLT buffer with equal 
volume 70% ethanol. The mix was then centrifuged in an RNeasy spin column, washed 
and concentrated until the final RNA was released into RNase free water. The quality and 
quantity was determined by ND-1000 spectrophotometer [NanoDrop Technologies 
Wilmington, DE] and reverse transcribed using iScriptTM cDNA synthesis kit [Bio-Rad 
Laboratories, CA] by following manufacturer’s instructions. 
4.2.2.2 qPCR  
 
Quantitative Real Time PCR was performed using SYBR Green Master Mix [Applied 
Biosystems, Foster City, CA] in an epgradient S Mastercycler [Eppendorf, NY]. The 
primers of interest were obtained from Integrated DNA Technologies [Coralville, IA] with 
the following sequences: OPA-1 (Forward 5’- CCTGTGAAGTCTGCCAATCC -3' and 
Reverse 5’- CTGGAAGATGGTGATGGGTT -3'), Mfn1 (Forward 5’-
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TCGTGCTGGCAAAGAAGG-3’ and Reverse 5’-CGATCAAGTTCCGGGTTCC-3’). 
GAPDH (Forward 5’ ATGATTCTACCCACGGCAAG 3’ and Reverse 5’ 
CTGGAAGATGGTGATGGGTT 3’) was used as the housekeeping gene. The ΔΔCT 
method was utilized for analysis of each target gene with respect to the housekeeping gene. 
 
4.2.3 Mitochondrial Morphology Imaging  
 
Mitotracker FM, green stain [Life Technologies, NY] was used for the specific staining of 
primary hepatocyte mitochondria. Live cells were washed with PBS and the dye was 
diluted to a concentration of 100 nM in Fluorobrite DMEM [Life Technologies, NY] and 
added to the cells. Cells were incubated at 37 ºC for 45 min and then washed extensively 
and imaged using confocal microscopy (Olympus FV500 IX 81).   
 
4.2.4 Statistical Analysis  
 
The difference between the various experimental groups was analyzed by a one-way 
analysis of variance (ANOVA) using the statistical analysis embedded in SigmaPlot 
Software using Tukey test. Q tests were employed to identify outliers in the data subsets. 
For statistical analysis of all data, p<0.05 was used as the threshold for significance. 
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4.3 Results 
 
4.3.1 Titanium Dioxide Nanoparticles and Oxidative Stress  
 
 We quantified the ROS production using CM-H2-DCFDA dye in order to measure the 
increased oxidized status of the cells in response to nanoparticles exposure (Fig. 15). At 
the concentrations of 20, 50 and 100 µg/ml, a type dependent increase in ROS production 
was observed when primary hepatocytes were exposed to TiO2 nanoparticles. The exposure 
of hepatocytes to 50 µg/ml of P25 and anatase resulted in relatively highest ROS 
production while exposure of the same concentration of rutile demonstrated lesser ROS 
production.  
 
 
 
 
 
Figure 15.   Characterizing the effect of nanoparticle treatment on primary hepatocyte 
mitochondrial functions; Quantification of Reactive Oxygen Species produced by primary 
hepatocytes using DCFDA based fluorescence assay after treatment with the different TiO2 
nanoparticles for a duration of 72 h. Significant difference with respect to control is denoted as * 
p value < 0.0001, # p value < 0.05 
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4.3.2 Titanium Dioxide Nanoparticles and Mitochondrial Dynamics  
 
To understand the effect of nanoparticle treatment on mitochondrial dynamics, we 
investigated the relative gene expressions of OPA-1 and Mfn-1 markers associated with 
mitochondrial fusion events (Fig. 16). OPA-1 and Mfn-1 gene expression levels were 
significantly down-regulated in hepatocytes when exposed to 50 µg/ml P25 and anatase 
with commercially used P25 having the highest effect. On the contrary, down-regulation 
of these markers in rutile treatment group was not substantial.  
 
 
 
Figure 16.   Characterizing the effect of nanoparticle treatment on primary hepatocyte 
mitochondrial functions; Relative gene expressions of mitochondrial fusion markers when 
primary hepatocytes are treated with nanoparticles at a concentration of 50 µg/ml as analyzed 
using qPCR with GAPDH as housekeeping gene. Significant difference with respect to control is 
denoted as * p value < 0.001 and # p value < 0.05  
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4.3.2 Titanium Dioxide Nanoparticles and Mitochondrial Morphology  
 
To probe the effect of the nanoparticles on the mitochondrial morphology and integrity, we 
imaged the mitochondria using the fluorescent stain Mitotracker FM (Fig. 17). The 
untreated primary hepatocytes depicted the typical fiber-like morphology indicating a 
healthy mitochondria. When hepatocytes were exposed to TiO2 nanoparticles, there was a 
significant loss in the fiber-like morphology and presence of high levels of fragmentation 
was also observed. 
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Figure 17. Fluorescent imaging of the mitochondrial morphology in primary rat hepatocytes 
after treatment with the different TiO2 nanoparticles at a concentration of 50ppm using 
Mitotracker green FM. Scale 20 microns.  
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4.4 Discussion 
 
To determine the underlying mechanism that potentially causes the loss in hepatic 
functions intracellular levels of ROS, a marker for oxidative stress, was measured in 
primary hepatocytes exposed to TiO2 nanoparticles. Numerous studies have demonstrated 
that metal oxide nanoparticle induced toxicity is primarily mediated by increased ROS 
production.48, 49 Our study indicates that anatase and P25 treated samples exhibit increased 
ROS production (Fig. 15). This higher production of ROS in P25 and anatase indicates that 
primary hepatocytes are in a high stress environment. 
In normal physiological conditions, mitochondrion is the main coordinator of ROS 
production that is key to maintaining a state of redox homeostasis in the cells, thereby 
protecting it from the damage of oxidative stress.51 When the ROS production is higher 
than the normal range, it results in an elevated state of oxidative stress and the cell responds 
by overworking the anti-oxidative pathways. Increase in ROS levels leads to DNA or 
protein denaturation, mitochondrial damage, lipid peroxidation, metabolic disorders and 
ultimately cell apoptosis.69-73 Several studies demonstrated that various environmental 
stresses lead to increased ROS production in cells.74  
Recent studies have emphasized the interrelationship of ROS and mitochondrial health, 
with respect to metabolic disorders and manifestation of various diseased states.75 
Excessive ROS causes mitochondrial dysregulation and comprises the mitochondrial 
dynamics resulting in a cyclic response that leads to excessive production of ROS. 
Mitochondria are extremely dynamic in nature and undergo continual fission and fusion 
processes which counterbalance each other, to alter the morphology that enables the cell to 
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meet its metabolic requirements and cope with internal or external stress. OPA1 and Mfn-
1 are markers known to be instrumental in regulating the fusion process in maintaining the 
mitochondrial dynamics. We observe a significant down-regulation in the gene expression 
levels of OPA1 and Mfn-1 in the 50 µg/ml treated hepatocytes, whereas, this down-
regulation was not observed in rutile samples. (Fig. 16) We also investigated the effect of 
nanoparticle treatment on fission event by probing Drp1, but we do not see a prominent 
change in the relative gene expression levels (data not shown). This indicates that the 
normal cellular balance between the fusion and fission events in mitochondria are disrupted 
by the nanoparticle treatment, through impairment in the fusion process. Mitochondrial 
fusion is vital in maintaining the respiratory functions of the organelle and any interference 
in this function can be detrimental to the bio-energetics, thereby causing a cascade of 
damage in the cells.  
Subsequently, we analyzed of the effect of the different nanoparticle treatment on primary 
hepatocyte mitochondrial morphology, to visualize the effect of disrupted mitochondrial 
dynamics. Fig. 17 displays that as compared to healthy untreated hepatocytes, the treated 
cells have fragmented and swollen mitochondria. Hepatocytes possess a unique 
mitochondrial organization wherein the mitochondria are spread throughout the cell body 
unlike other cells where the mitochondria are concentrated around the cell nuclei and 
concentration decreases radially. Loss in the typical fiber-like morphology and increase in 
fragmentation is a strong indication of compromise in the mitochondria dynamics.  This is 
also in sync with our observation where OPA-1 and Mfn-1 were significantly down-
regulated in hepatocytes exposed to TiO2 nanoparticles. Defects in mitochondrial fusion 
result in mitochondria that appear swollen and spherical, instead of fiber-like. Together, 
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these results provide confirmative proof that exposure to TiO2 nanoparticles even at 
concentration as low as 50 µg/ml results in significant mitochondrial damage by 
interrupting the fusion-fission equilibrium and affecting the mitochondrial dynamics.76  
 
4.5 Conclusion 
 
We observe that Titanium Dioxide Nanoparticles lead to a state of Oxidative Stress due to 
overproduction of Reactive Oxygen Species. ROS production was most upregulated in P25 
treated samples, followed by anatase and then rutile. Mitochondrial fusion markers Opa1 
and Mfn1 showed a downregulation in the gene expression, indicating towards the 
disruption of mitochondrial dynamics, through loss in the fusion event. We stained the 
mitochondrial fibers using Mitotracker and visualized that the nanoparticle treatment of 
P25 and anatase resulted in abnormal mitochondrial morphology. These results collectively 
suggest a state of oxidative stress and mitochondrial damage in primary hepatocytes when 
treated with TiO2 Nanoparticles.  
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Chapter 5 Conclusions   
 
Overall, we observed that exposure of primary rat hepatocytes to different types of 
commercially available TiO2 nanoparticles cause toxicological effects in the cells. We note 
a modest loss in cell viability. However, hepatic specific functions, urea and albumin 
synthesis, are significantly compromised due to TiO2 nanoparticles exposure within 72 h 
even at concentrations as low as 20 µg/ml. We observed an increase the amount of 
intracellular ROS production when hepatocytes are exposed to TiO2 nanoparticles, which 
is indicative of oxidative stress related damages. Finally, we observe that exposure to TiO2 
nanoparticles results in significant mitochondrial damage as seen in the down-regulation 
of OPA1 and Mfn-1, markers that is indicative of the fusion cycle that is key to maintaining 
the mitochondrial dynamics. This decreased levels of Mfn-1 and OPA1 results in the 
fragmented mitochondrial network in hepatocytes exposed to TiO2 nanoparticles and is a 
strong indicator of the disruption of the mitochondrial dynamics. From these observations, 
we propose that TiO2 nanoparticles induce cytotoxicity of hepatocytes by (1) down-
regulating the fusion process thus disrupting the mitochondrial dynamics, (2) inducing 
damages to the mitochondrial morphology, (3) triggering oxidative stress mediated by an 
increase in ROS production that is associated with loss of cell viability, and (4) inducing 
loss in hepatic functions including urea and albumin (Fig. 18). Therefore, we propose that 
TiO2 nanoparticles could potentially contribute to subsequent adverse health effects and 
the development of liver diseases such as liver fibrosis.  
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Figure 18. Schematic representation of the possible damaging role of TiO2 nanoparticles on 
primary hepatocytes. We propose that TiO2 induces loss in hepatic functions on primary 
hepatocytes through the induction of oxidative stress mediated by an increase of ROS production, 
and significant mitochondria damage by down-regulating the fusion cycle in the mitochondrial 
dynamics.  
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Chapter 6 Future Studies  
   
1. Detailed exploration of the biochemical pathways related to mitochondrial 
respiration and mitochondrial stress mediated cell death pathways will aid in a 
better understanding of the toxicity effects observed. 
2. We also propose that mitochondrial stress has the potential to be used as an early 
and sensitive marker for nanotoxicological studies and can also supplement studies 
aimed at designing better therapeutic measures to combat nanomaterial and other 
engineered materials toxicity.  
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